Disitamab vedotin( —— )

Catalog No. M35132 CAS No. 2136633-23-1

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

Disitamab vedotin
Note

Research use only, not for human use.
Brief Description

Disitamab vedotin (RC-48) is a newly developed antibody-active molecule conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), consisting of hertuzumab coupled to monomethyl auristatin E (MMAE) via a cleavable linker.
Description

Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity.
In Vitro

The antibody part was a humanized monoclonal antibody targeting HER2, the small molecule toxin was monomethyl auristatin E (MMAE), a synthetic antineoplastic agent. A protease cleavable linker covalently attached MMAE to the antibody.
In Vivo

——
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

Antibody-Drug Conjugates (ADCs) | EGFR
Research Area

——
Indication

——

1. Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81(16):1929-1935.?

Calculator

molnova catalog